Hypothermic microenvironment plays a key role in tumor immune subversion

International Immunopharmacology

Volumn 17, Issue 2, 2013, Pages 245-253

  Du, Gangjun ^a   Liu, Yinghui ^a   Li, Jiahuan ^a   Liu, Weijie ^a   Wang, Yingying ^a   Li, Hong ^a  

^a HENAN UNIVERSITY   (China)

Author keywords

Hyperthermia; Hypothermia; Immunosuppressive microenvironment; Tumorigenesis

Indexed keywords

CAPSAICIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; HYPOTHERMIA; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TEMPERATURE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

3-(4,5)-DIMETHYLTHIAHIAZO(-Z-Y1)-3,5-DI-PHENYTETRAZOLIUMROMIDE; CARBOXYFLUORESCEIN SUCCINIMIDYL ESTER; CFSE; ELISA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FBS; FCM; FETAL BOVINE SERUM; FLOW CYTOMETRY; HYPERTHERMIA; HYPOTHERMIA; IFN-Γ; IL-; IMMUNOSUPPRESSIVE MICROENVIRONMENT; INTERFERON-GAMMA; INTERLEUKIN-; LEWIS LUNG CANCER; LLC; MTT; PHORBOL MYRISTATE ACETATE; PMA; REGULATORY T CELL; TGF-Β1; TRANSFORMING GROWTH FACTOR-Β1; TREG; TUMORIGENESIS;

ANIMALS; CAPSAICIN; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; COLD TEMPERATURE; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; EPINEPHRINE; HOT TEMPERATURE; HYPERTHERMIA, INDUCED; HYPOTHERMIA, INDUCED; IMMUNOSUPPRESSION; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MICROCIRCULATION; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH1-TH2 BALANCE; TH2 CELLS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84880182003     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.06.018     Document Type: Article

References (38)

1. Prevarskaya N, Skryma R, Shuba Y. Calcium in tumour metastasis: new roles for known actors. Nat Rev Cancer 2011;11:609-18.
2. Morita R, Hirohashi Y, Sato N. Depletion of Tregs in vivo: a promising approach to enhance antitumor immunity without autoimmunity. Immunotherapy 2012;4: 1103-5.
3. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the mass. Science 2004;305:200-5.
4. Murala S, Alli V, Kreisel D, Gelman AE, Krupnick AS. Current status of immunotherapy for the treatment of lung cancer. J Thorac Dis 2010;2:237-44.
5. Xu L, Xiao H, Xu M, Zhou C, Yi L, Liang H. Glioma-derived T cell immunoglobulinand mucin domain-containing molecule-4 (TIM4) contributes to tumor tolerance. J Biol Chem 2011;286:36694-9.
6. Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012;104:599-613.
7. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012;482:400-4.
8. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 2010;70:9053-61.
9. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One 2008;3:e2599.
10. Tchou J, Conejo-Garcia J. Targeting the tumor stroma as a novel treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a stroma-centric paradigm. Adv Pharmacol 2012;65:45-61.
11. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62. (Pubitemid 40093472)
12. Roden MM, Lee KH, Panelli MC, Marincola FM. A novel cytolysis assay using fluorescent labeling and quantitative fluorescent scanning technology. J Immunol Methods 1999;226:29-41. (Pubitemid 29336528)
13. Ehi K, Ishigami S, Masamoto I, Uenosono Y, Natsugoe S, Arigami T, et al. Analysis of T-helper type1 and 2 cells and T-cytotoxic type 1 and 2 cells of sentinel lymph nodes in breast cancer. Oncol Rep 2008;19:601-7. (Pubitemid 351330424)
14. Lathers DM, Achille NJ, Young MR. Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck. Hum Immunol 2003;64:1160-6. (Pubitemid 37475277)
15. Music M, Finderle Z, Cankar K. Cold perception and cutaneous microvascular response to local cooling at different cooling temperatures. Microvasc Res 2011;81: 319-24.
16. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565-70.
17. Shobo M, Kondo Y, Yamada H, Mihara T, Yamamoto N, Katsuoka M, et al. Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake. J Pharmacol Exp Ther 2010;333:772-81.
18. Zhou J, Wang X, Du L, Zhao L, Lei F, Ouyang W, et al. Effect of hyperthermia on the apoptosis and proliferation of CaSki cells. Mol Med Rep 2011;4:187-91.
19. Essand M, Loskog AS. Genetically engineered T cells for the treatment of cancer. J Intern Med 2013;273:166-81.
20. Tamura Y, Torigoe T, Kukita K, Saito K, Okuya K, Kutomi G, et al. Heat-shock proteins as endogenous ligands building a bridge between innate and adaptive immunity. Immunotherapy 2012;4:841-52.
21. Kumar S, Deepak P, Acharya A. Autologous Hsp70 immunization induces anti-tumor immunity and increases longevity and survival of tumor-bearing mice. Neoplasma 2009;56:259-68.
22. Quezada SA, Peggs KS, Simpson TR, Allison JP. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev 2011;241: 104-18.
23. Charoentong P, Angelova M, Efremova M, Gallasch R, Hackl H, Galon J, et al. Bioinformatics for cancer immunology and immunotherapy. Cancer Immunol Immunother 2012;61:1885-903.
24. Umansky V. New strategies for melanoma immunotherapy: how to overcome immunosuppression in the tumor microenvironment. Oncoimmunology 2012;1: 765-7.
25. Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, et al. Anaphylatoxin c5a creates a favorable microenvironment for lung cancer progression. J Immunol 2012;189:4674-83.
26. Capece D, Verzella D, Fischietti M, Zazzeroni F, Alesse E. Targeting costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol 2012;2012: 926321.
27. Guillaume B, Stroobant V, Bousquet-Dubouch MP, Colau D, Chapiro J, Lambris JD, et al. Analysis of the processing of seven human tumor antigens by intermediate proteasomes. J Immunol 2012;189:3538-47.
28. Liao Y, Schaue D, McBride WH. Modification of the tumor microenvironment to enhance immunity. Front Biosci 2007;12:3576-600.
29. Iwen KA, Wenzel ET, Ott V, Perwitz N, Wellhöner P, Lehnert H, et al. Cold-induced alteration of adipokine profile in humans. Metabolism 2011;60:430-7.
30. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006;213:131-45. (Pubitemid 44401498)
31. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235-71.
32. Redjimi N, Raffin C, Raimbaud I, Pignon P, Matsuzaki J, Odunsi K, et al. CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. Cancer Res 2012;72:4351-60.
33. Yamagami W, Susumu N, Tanaka H, HIrasawa A, Banno K, Suzuki N, et al. Immunofluorescencedetected infiltration of CD4+ FOXP3+ regulatory T cells is relevant to the prognosis of patients with endometrial cancer. Int J Gynecol Cancer 2011;21:1628-34.
34. Weiss VL, Lee TH, Jaffee EM, Armstrong TD. Targeting the right regulatory T-cell population for tumor immunotherapy. Oncoimmunology 2012;1:1191-3.
35. Gigante M, Gesualdo L, Ranieri E. TGF-beta: a master switch in tumor immunity. Curr Pharm Des 2012;18:4126-34.
36. Asanami S, Shimono K, Kaneda S. Transient hypothermia induces micronuclei in mice. Mutat Res 1998;413:7-14. (Pubitemid 28218241)
37. Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, Marti HH, et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008;453:410-4. (Pubitemid 351693122)
38. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 2012;109:17561-6.